Chiba, Japan, November 12, 2026 ― Researchers in Japan have, for the first time, visualized the activity of an important liver enzyme in vivo using an MRI-based approach, potentially providing a new way to detect and monitor fatty liver disease. The condition can progress with few obvious warning signs and, in severe cases, can lead to liver inflammation, fibrosis, cirrhosis and liver cancer.
A joint research team led by Yoichi Takakusagi at the National Institutes for Quantum Science and Technology (QST), together with Daichi Kaneko and Akari Ikeda of Nippon Sanso Corporation and other collaborators, developed a molecular probe that enables the activity of an enzyme called paraoxonase (PON) to be visualized using hyperpolarized MRI. In mouse models of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), the researchers found that PON activity declined as the disease progressed. This study was published in Sensors & Diagnostics on November 12, 2026.
MASLD is a common condition in which excess fat builds up in the liver in association with metabolic disorders. It is estimated to affect about one in three adults. In some people, the disease progresses to MASH, liver fibrosis, cirrhosis and even liver cancer. PON, which is mainly produced in the liver, is involved in lipid metabolism and protecting against oxidative stress. Its activity has therefore attracted attention as a potential marker of metabolic changes in the liver. However, conventional blood tests cannot accurately reflect how the enzyme functions within the liver itself, where its activity is strongly influenced by the local biological environment.
To make that activity visible, the team designed a probe based on carbon-13-labelled mevalonolactone, or [1-¹³C]MVL. PON converts MVL into mevalonic acid (MVA). By detecting both molecules and comparing their signals, the researchers can visualize PON activity in the liver.
The researchers used a technique called hyperpolarization to temporarily boost the probe's MRI signal. Using a SpinAligner hyperpolarizer installed at QST's Institute for Quantum Life Science, the team achieved approximately 230,000-fold signal enhancement compared with conventional MRI conditions. The enhanced signal persisted long enough to detect both the probe and its metabolic product in vivo. In mice, a scan of about 20 seconds was sufficient to visualize PON activity in the liver.
The team then tested the approach in mice fed a special diet that induces MASLD and MASH. Compared with healthy control mice, the disease-model mice showed a progressive decline in liver PON activity as the disease progressed. These findings show that the probe can noninvasively detect disease-associated changes in enzyme activity in the living liver with high sensitivity.
"We wanted to find a way to see what enzymes are actually doing inside the living body, rather than relying only on blood tests," said Yoichi Takakusagi, Group Leader at QST's Institute for Quantum Life Science. "The biggest challenge was developing a probe that produced a strong enough signal while still responding specifically to PON activity. Our new probe overcame that hurdle, allowing us to visualize changes in enzyme activity associated with the progression of fatty liver disease."
The researchers say the implications could eventually extend beyond liver disease. By adapting the molecular-probe design to other enzymes, hyperpolarized MRI could open the way to a new class of imaging methods that visualize biochemical activity rather than anatomical changes alone. In the longer term, such techniques could contribute to earlier disease detection, assessment of disease progression, and more individualized treatment planning.